The RhoGAM story never gets old
The original Rh-negative breakthrough that has protected generations of babies.1-4
The remarkable true story of one of the greatest medical breakthroughs of the 20th century.
Before the 1960s, there was no method available to prevent Rh sensitization during Rh-incompatible pregnancies. Rh sensitization can result in hemolytic disease of the fetus and newborn (HDFN), a condition in which the red blood cells of the fetus are destroyed by the mother's antibodies.2,5 This condition can have serious effects for the baby.2,5 At that time, HDFN affected 9%-10% of all pregnancies and contributed significantly to fetal deaths in the US.6 Innovators were needed for this complex problem.
"Before it's a breakthrough it's a crazy idea."
A team of scientists were convinced that an unconventional theory known as passive antibody immunosuppression could help prevent Rh sensitization. The idea is to provide the body with passive antibodies so that it doesn't produce its own antibodies which would result in a more active immune response. If passive Rh antibodies were given to an Rh-negative mother, it would reduce her body's attempt to produce active antibodies against her baby.7-9 In a way, passive antibodies "fool" a mother's immune system into thinking it has already produced a response.
"A story of heroism and triumph. Of brilliant science and generous empathy."
At first the idea wasn't well received by the scientific community. But the research team remained dedicated to their dream. As a result, in 1968, the FDA approved the use of RhoGAM to help prevent Rh immunization.10 As the first anti-D product available, RhoGAM has given hope to Rh-negative mothers by protecting generations of Rh-positive babies for 5 decades.1-4
Read about the heroes behind
